---
search:
  boost: 3
---

# Neuropathic Pain

This is a subcategory of Central Nervous System (CNS) Agents.

## Formulary

### Preferred

| Preferred                          | Generic Name                                                  | Quantity | Time (Days) |
| :--------------------------------- | :------------------------------------------------------------ | :------: | :---------: |
| Amitriptyline                      |                                                               |          |             |
| Carbamazepine                      |                                                               |          |             |
| Desipramine                        |                                                               |          |             |
| Doxepin 10, 25, 50, 75, 100, 150mg |                                                               |          |             |
| Doxepin Sol                        |                                                               |          |             |
| Duloxetine <sup>QL</sup>           | Duloxetine HCI Enteric Pellets Cap (all strengths excl 30 MG) |   204    |     102     |
| Duloxetine <sup>QL</sup>           | Duloxetine HCI Enteric Pellets Cap 30 MG                      |   306    |     102     |
| Gabapentin <sup>QL</sup>           | Gabapentin Cap/Tab 100 MG                                     |   204    |     34      |
| Gabapentin <sup>QL</sup>           | Gabapentin Cap/Tab 300 MG                                     |   408    |     34      |
| Gabapentin <sup>QL</sup>           | Gabapentin Cap/Tab 400 MG                                     |   306    |     34      |
| Gabapentin <sup>QL</sup>           | Gabapentin Tab 600 MG                                         |   204    |     34      |
| Gabapentin <sup>QL</sup>           | Gabapentin Tab 800 MG                                         |   136    |     34      |
| Gabapentin <sup>QL</sup>           | Gabapentin Oral Soln 250 MG / 5 ML                            |   2448   |     34      |
| Imipramine                         |                                                               |          |             |
| Lidocaine Patch                    |                                                               |          |             |
| Nortriptyline                      |                                                               |          |             |
| Oxcarbazepine                      |                                                               |          |             |
| Pregabalin <sup>QL</sup>           | Pregabalin Cap (all strengths excl 225 MG & 300 MG)           |   102    |     34      |
| Pregabalin <sup>QL</sup>           | Pregabalin Cap 225 MG & 300 MG                                |    68    |     34      |

### Non-Preferred

| Non-Preferred | Generic Name | Quantity | Time (Days) |
| :------------ | :----------- | :------: | :---------: |
| Gralise       |              |          |             |
| Horizant      |              |          |             |
| Pregabalin ER |              |          |             |
| Ztlido        |              |          |             |

## Authorizations

**Length of Authorizations**: 365 Days

**All Authorizations**: Must be prescribed in accordance with FDA approved labeling

## Criteria

### Non-Preferred

Non-Preferred Criteria

- Must provide documentation of medical necessity beyond convenience for why the patient cannot be changed to a preferred drug (i.e., allergies, drug-drug interactions, contraindications, or intolerances) **OR**
    - For any nonsolid oral dosage formulation: must provide documentation of medical necessity for why patient cannot be changed to a solid oral dosage formulation
- Must have had an inadequate clinical response of at least **30 days** with at least **two preferred** drugs
    - For non-preferred extended-release formulations: must provide documentation of an inadequate clinical response with its immediate release formulation (if available)
    - For non-preferred brand names that have preferred generics: must provide documentation of an inadequate clinical response or allergy to two or more generic labelers (if available)

### Subsequent Authorization

Subsequent Authorization Criteria

- Must provide documentation of patient's clinical response to treatment and ongoing safety monitoring

## Links

[Criteria](https://pharmacy.medicaid.ohio.gov/sites/default/files/20230401_UPDL_Criteria%20_APPROVED.pdf#page=44){ :target="_blank" rel="noopener"}

[Preferred Drug List](https://pharmacy.medicaid.ohio.gov/sites/default/files/20230401_UPDL_v7_Approved.pdf#page=17){ :target="_blank" rel="noopener"}

[Quantity Limit List](https://pharmacy.medicaid.ohio.gov/sites/default/files/20230101_Ohio_Medicaid_Quantity_Document_APPROVED.pdf){ :target="_blank" rel="noopener"}
